Company Aims to Increase national Awareness and Continues to Expand its Distribution Network to Licensed Naturopathic Physicians
LAS VEGAS, NV – (Marketwired – June 27, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), today announced that its industry-dominating brand of hemp-derived cannabidiol oil finished products, PlusCBD Oil™, will be exhibiting at the American Association of Naturopathic Physicians (AANP) 2017 National Conference, held on July 12-15, 2017 at The Arizona Biltmore in Phoenix, AZ.
As the professional association that represents licensed naturopathic physicians, the AANP strives to make naturopathic medicine available to every American and to increase recognition of naturopathic physicians as the identified authorities on natural medicine. Over the last three years, the Company’s consumer products division has focused on distributing their PlusCBD Oil™ brand to healthcare providers nationwide.
“Naturopathic physicians truly understand the power of botanical nutrition. We are elated to see the tremendous growth of PlusCBD Oil™ amongst licensed practitioners and the AANP’s Annual Conference has been integral in supporting the forward-thinking understanding around this promising ingredient. CV Sciences’ continued participation has led to an increase in our distribution network and as a result, has impacted our top line growth,” states Stuart Tomc, VP of Human Nutrition at CV Sciences. “We are extremely excited to showcase our array of products and educate clinicians on current practical and nutritional benefits of hemp-derived CBD.”
VISIT BOOTH 210: CV Sciences invites attendees to visit Booth 210 to learn more about their botanical‐based CBD product line. The Company will additionally feature its brand of practitioner-exclusive products available only to healthcare providers nationwide. Also, CV Sciences will be offering exclusive trade show discounts and show specials to practitioners attending the show.
EXHIBITOR-SPONSORED PRESENTATION: Join the CV Sciences team for an interactive presentation, “Hemp-derived CBD: The Missing Ingredient in your Tool Kit,” on Thursday, July 13th, 2017 at 10 am in the AANP Conference Exhibit Hall at the Arizona Biltmore. Presented by Aimée Shunney, ND, Medical Advisor to CV Sciences, the presentation will cover the interactions of CBD and the human endocannabinoid system as it relates to human health, the importance of proper quality control measures to ensure safety and efficacy, and how CV Sciences demonstrates Full Traceability – From Seed to Shelf™.
NATURAL PARTNERS PANEL: CV Sciences is honored to participate in practitioner wholesale distributor Natural Partners’ Roundtable Panel entitled, “CBD: State of the Science, Clinical Applications and What We Know,” on Friday, July 14th, 2017 in the Prescott Room at the Arizona Biltmore. Speaking from her experience as a clinician, Dr. Shunney, along with a variety of panelists, will be covering various discussion topics around the CBD conversation: from sourcing to quality control to clinical applications. Attendees are encouraged to come early as seating is limited.
For more information or to schedule a meeting with the Company management, please contact Robert Haag at firstname.lastname@example.org.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.